Respirerx Pharmaceuticals Inc. (RSPI) SEC Filing 10-Q Quarterly Report for the period ending Thursday, March 31, 2022

SEC Filings

Respirerx Pharmaceuticals Inc.

CIK: 849636 Ticker: RSPI
Cover - shares
3 Months Ended
Mar. 31, 2022
May 18, 2022
Cover [Abstract]  
Document Type10-Q 
Amendment Flagfalse 
Document Quarterly Reporttrue 
Document Transition Reportfalse 
Document Period End DateMar. 31, 2022 
Document Fiscal Period FocusQ1 
Document Fiscal Year Focus2022 
Current Fiscal Year End Date--12-31 
Entity File Number1-16467 
Entity Central Index Key0000849636 
Entity Tax Identification Number33-0303583 
Entity Incorporation, State or Country CodeDE 
Entity Address, Address Line One126Valley Road 
Entity Address, Address Line TwoSuite C 
Entity Address, City or TownGlenRock 
Entity Address, State or ProvinceNJ 
Entity Address, Postal Zip Code07452 
City Area Code(201) 
Local Phone Number444-4947 
Entity Current Reporting StatusYes 
Entity Interactive Data CurrentYes 
Entity Filer CategoryNon-accelerated Filer 
Entity Small Businesstrue 
Entity Emerging Growth Companyfalse 
Entity Shell Companyfalse 
Entity Common Stock, Shares Outstanding 102,774,276

View differences made from one quarter to another to evaluate Respirerx Pharmaceuticals Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Respirerx Pharmaceuticals Inc..


Assess how Respirerx Pharmaceuticals Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Respirerx Pharmaceuticals Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Condensed Consolidated Statements Of Stockholders' Deficiency (Unaudited)
Business (Details Narrative)
Commitments And Contingencies
Commitments And Contingencies (Details Narrative)
Commitments And Contingencies (Tables)
Notes Payable
Notes Payable (Details Narrative)
Notes Payable (Tables)
Organization And Basis Of Presentation
Related Party Transactions
Related Party Transactions (Details Narrative)
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share (Details)
Schedule Of Convertible Notes Outstanding (Details)
Schedule Of Convertible Notes Payable (Details)
Schedule Of Exercise Prices Of Common Stock Options Outstanding And Exercisable (Details)
Schedule Of Exercise Prices Of Common Stock Warrants Outstanding And Exercisable (Details)
Schedule Of Warrants Activity (Details)
Settlement And Payment Agreements
Settlement And Payment Agreements (Details Narrative)
Stockholders??? Deficiency
Stockholders??? Deficiency (Details Narrative)
Stockholders??? Deficiency (Tables)
Subsequent Events
Subsequent Events (Details Narrative)
Summary Of Current Cash Commitments In Employment Agreements (Details)
Summary Of Principal Cash Obligations And Commitments (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details Narrative)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Stock Option Activity (Details)

Material Contracts, Statements, Certifications & more

Respirerx Pharmaceuticals Inc. provided additional information to their SEC Filing as exhibits

Ticker: RSPI
CIK: 849636
Form Type: 10-Q Quarterly Report
Accession Number: 0001493152-22-014786
Submitted to the SEC: Mon May 23 2022 4:06:01 PM EST
Accepted by the SEC: Mon May 23 2022
Period: Thursday, March 31, 2022
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: